Immunic, Inc.
IMUXHealthcare|Biotechnology|US
$7.75
+0.43 (+5.87%)
DCF Value
$0.60
Tangible Book / Share
$3.00
Cash / Share
$3.65
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Active | 1,100 | RCT, Double-blind | IMU-838 tablets, Placebo matching IMU-838 tablets |
| NCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | P3 | Active | 1,121 | RCT, Double-blind | IMU-838 tablets, Placebo matching IMU-838 tablets |
| NCT03846219 MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) | Relapsing-Remitting Multiple Sclerosis (RRMS) | P2 | Active | 210 | RCT, Double-blind | IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo, IMU-838 (10 mg/day) |
| NCT04379271 A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) | COVID-19 | P2P3 | Completed | 234 | RCT, Double-blind | IMU-838 |
| NCT03341962 Phase 2 Dose-finding IMU-838 for Ulcerative Colitis | Ulcerative Colitis | P2 | Terminated | 263 | RCT, Double-blind | IMU-838, Placebo |
| NCT04516915 IMU-838 and Oseltamivir in the Treatment of COVID-19 | Covid 19 | P2 | Completed | 38 | RCT, Open-label | IMU-838, Oseltamivir |
| NCT05054140 Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis | Multiple Sclerosis | P2 | Unknown | 450 | RCT, Double-blind | IMU-838, Placebo matching IMU-838 |
| NCT05124795 IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Metastatic Castration Resistant Prostate Cancer | P1 | Terminated | 18 | Open-label | IMU-935 |